newsfilter
← Latest News
Business Wire·

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

-- Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 -- Omeros Corporation (NASDAQ:OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3